Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (358)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02173119 | Can Quantitative MRI After cTACE Help Predict Survival ? | completed | — | 23 | Medical College of WisconsinOTHER | 1 | Jun 10, 2019 | clinicaltrials |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma(LD-FOX4/HCC) | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT03919383 | Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT01126645 | Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer(SORAMIC) | completed | Phase 2 | 529 | University of MagdeburgOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03966209 | Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT00901901 | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma(SEARCH) | completed | Phase 3 | 732 | BayerINDUSTRY | 26 | May 30, 2019 | clinicaltrials |
| NCT03950102 | SBRT as Bridging Therapy for Hepatocellular Carcinoma Patients on Transplant Waitlist | unknown | N/A | 40 | The University of Hong KongOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT03880721 | By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation | unknown | — | 200 | Chinese PLA General HospitalOTHER | 1 | May 24, 2019 | clinicaltrials |
| NCT03300401 | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT03138044 | Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma | unknown | N/A | 12 | The National Ribat UniversityOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT01290523 | Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma | terminated | N/A | 14 | University of California, San FranciscoOTHER | 1 | May 13, 2019 | clinicaltrials |
| NCT01008917 | Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | completed | Phase 1 | 25 | University of California, San FranciscoOTHER | 1 | May 9, 2019 | clinicaltrials |
| NCT03939845 | A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi | unknown | Phase 3 | 180 | Shanghai Zhongshan HospitalOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT00586235 | Registration and Fusion of Real-Time Ultrasound With CT for Lesion Localization and Characterization | completed | — | 80 | Mayo ClinicOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03775707 | Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 2 | 0 | Shi MingOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03782831 | TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT02471313 | Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization | completed | Phase 2 | 3 | National Institutes of Health Clinical Center (CC)NIH | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03746249 | Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03812770 | Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03914352 | A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection | unknown | N/A | 40 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01676194 | Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma(CATCH) | terminated | Phase 3 | 7 | Rennes University HospitalOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03300414 | Biologic Basis of Liver Cancer From Chronic Hepatitis B | completed | — | 2 | University of California, DavisOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT03899415 | TCR-Redirected T Cells Therapy in Patient With HBV Related HCC | unknown | Phase 1 | 10 | Beijing 302 HospitalOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT03908840 | Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 12 | Evolve BiologicsINDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies | terminated | Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT03869151 | Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients | unknown | — | 1 | Amany Aboalenen AminOTHER | 0 | Apr 2, 2019 | clinicaltrials |
| NCT03857815 | Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03881501 | Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma | unknown | — | 2 | Huazhong University of Science and TechnologyOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT00397540 | The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) | completed | N/A | 145 | Seoul National University HospitalOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT01952353 | Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion | completed | Phase 4 | 330 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01229839 | Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC | completed | Phase 3 | 668 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01259414 | Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma | completed | Phase 3 | 812 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT02981498 | Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT02151864 | LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis | completed | Phase 1 | 9 | Jason K. Sicklick, M.D.OTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01891539 | Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma(DEBDOX) | unknown | — | 100 | International Group of Endovascular OncologyOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02587793 | Primary Culture of Residual Specimens Obtained From Aspiration of Hepatic Tumor to Predict the Prognosis of the Patients | completed | — | 208 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03853928 | Probiotics in the Prevention of Hepatocellular Carcinoma in Cirrhosis | unknown | N/A | 280 | Austral University, ArgentinaOTHER | 0 | Feb 27, 2019 | clinicaltrials |
| NCT02232490 | Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L(Hepko-V5) | unknown | Phase 3 | 120 | Immunitor LLCINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02267213 | Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 29 | Taiwan Liposome CompanyINDUSTRY | 2 | Feb 26, 2019 | clinicaltrials |
| NCT02425605 | Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 47 | Yonsei UniversityOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT03852238 | Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)(NoFlic) | completed | — | 283 | University Hospital, BordeauxOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT03851887 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03851939 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Jun 10, 2019source: clinicaltrials